AU2006298677A1 - Phosphoantigen salts of organic bases and methods for their crystallization - Google Patents

Phosphoantigen salts of organic bases and methods for their crystallization Download PDF

Info

Publication number
AU2006298677A1
AU2006298677A1 AU2006298677A AU2006298677A AU2006298677A1 AU 2006298677 A1 AU2006298677 A1 AU 2006298677A1 AU 2006298677 A AU2006298677 A AU 2006298677A AU 2006298677 A AU2006298677 A AU 2006298677A AU 2006298677 A1 AU2006298677 A1 AU 2006298677A1
Authority
AU
Australia
Prior art keywords
phosphoantigen
salt
group
crystalline
organic base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006298677A
Other languages
English (en)
Inventor
Eric Aubin
Gerard Coquerel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of AU2006298677A1 publication Critical patent/AU2006298677A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3895—Pyrophosphonic acids; phosphonic acid anhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/098—Esters of polyphosphoric acids or anhydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006298677A 2005-10-06 2006-10-05 Phosphoantigen salts of organic bases and methods for their crystallization Abandoned AU2006298677A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72430805P 2005-10-06 2005-10-06
US60/724,308 2005-10-06
PCT/EP2006/067089 WO2007039635A2 (en) 2005-10-06 2006-10-05 Phosphoantigen salts of organic bases and methods for their crystallization

Publications (1)

Publication Number Publication Date
AU2006298677A1 true AU2006298677A1 (en) 2007-04-12

Family

ID=37776880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006298677A Abandoned AU2006298677A1 (en) 2005-10-06 2006-10-05 Phosphoantigen salts of organic bases and methods for their crystallization

Country Status (8)

Country Link
US (1) US20080300222A1 (enExample)
EP (1) EP1933848A2 (enExample)
JP (1) JP2009511449A (enExample)
CN (1) CN101282730A (enExample)
AU (1) AU2006298677A1 (enExample)
CA (1) CA2624533A1 (enExample)
EA (1) EA200801028A1 (enExample)
WO (1) WO2007039635A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324040B1 (en) * 2008-09-10 2014-01-01 Innate Pharma Novel polymorphic form of chdmapp, method of preparation thereof, and pharmaceutical composition comprising same
EP2669312A1 (en) 2012-05-29 2013-12-04 Huntsman International Llc Process for the production of polyether polyols

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056812A (en) * 1958-08-08 1962-10-02 Glaxo Lab Ltd Steroid 21-pyrophosphate esters
DE1153373B (de) * 1960-09-17 1963-08-29 Shell Int Research Verfahren zur Herstellung von Pyrophosphorsaeureestern, Phosphorsaeureestern, -amiden oder -carbonsaeureanhydriden
GB1395820A (en) * 1971-06-05 1975-05-29 Villax I Preparation of 21-inorganic esters of corticosteroids and salts thereof
GB1580899A (en) * 1976-07-27 1980-12-10 Fujisawa Pharmaceutical Co Hydroxyaminohydrocarbonphosphonic acid derivatives and production and use thereof
EP0350672A1 (en) * 1988-06-28 1990-01-17 MAGIS FARMACEUTICI S.p.A. Salts of diacyl-glycero-(di)-phosphates of L-(acyl) carnitine and of L-acyl-carnitine esters
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
TW401276B (en) * 1993-10-07 2000-08-11 Zeneca Ltd Novel compounds and a method of controlling growth of plants
FR2715660A1 (fr) * 1994-01-28 1995-08-04 Centre Nat Rech Scient Composés organo-phosphorés activateurs des lymphocytes Tgammadelta, procédé pour préparer et/ou isoler et/ou caractériser ces composés, compositions et utilisations pharmaceutiques.
ES2225958T3 (es) * 1996-10-09 2005-03-16 Pharmasset, Ltd. Compuestos bisfonato micofenolicos.
DE69942645D1 (en) * 1998-01-09 2010-09-16 Body Corporate Of The State Of Synthese von combretastatin a-4 prodrugs
US6750340B2 (en) * 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
FR2791981B1 (fr) * 1999-04-06 2001-07-20 Inst Nat Sante Rech Med Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications
SE9903345D0 (sv) * 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
DE10201458A1 (de) * 2001-04-11 2002-10-17 Adelbert Bacher Intermediate und Enzyme des Mevalonat-unabhängigen Isoprenoidbiosyntheseweg
CA2453817C (en) * 2001-07-20 2011-09-20 Bioagency Ag Organophosphorus compounds for the activation of gamma/delta t-cells
FR2833266B1 (fr) * 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
AU2003217863B9 (en) * 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
US7767842B2 (en) * 2002-12-02 2010-08-03 Innate Pharma Sa Class of γδ T cells activators and use thereof
WO2005066190A1 (en) * 2004-01-02 2005-07-21 Hexal A/S New risedronate salts
CN101146575A (zh) * 2005-03-22 2008-03-19 依奈特制药公司 新类型的γδT细胞活化剂及其应用

Also Published As

Publication number Publication date
US20080300222A1 (en) 2008-12-04
WO2007039635A3 (en) 2007-06-21
JP2009511449A (ja) 2009-03-19
CA2624533A1 (en) 2007-04-12
WO2007039635A2 (en) 2007-04-12
EP1933848A2 (en) 2008-06-25
CN101282730A (zh) 2008-10-08
EA200801028A1 (ru) 2008-10-30

Similar Documents

Publication Publication Date Title
US6767900B2 (en) Phosphonate nucleotide compound
AU747163B2 (en) Nucleotide analog compositions
AU2014268040B2 (en) Phosphoric acid/phosphonic acid derivatives and medicinal uses thereof
KR101178319B1 (ko) 포스폰산 유도체 및 ｐ2ｙ12 수용체 길항물질로서 이들의 용도
JP4033494B2 (ja) ヌクレオチドアナログ
CA2751392A1 (en) Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
TW200408645A (en) Non nucleoside reverse transcriptase inhibitors
EP2160394A1 (en) Tenofovir disoproxil hemi-fumaric acid co-crystal
CA2890676A1 (en) Phosphonucleosides useful in the treatment of viral disorders
JPH0259833B2 (enExample)
KR100619298B1 (ko) 뉴클레오타이드 동족체
CA2533966A1 (en) Nucleobase phosphonate analogs for antiviral treatment
CN102228463B (zh) 泰诺福韦的晶体
KR102476361B1 (ko) 테노포비르 프로드럭의 신규 다결정형 및 이의 제조방법 및 적용
US20080300222A1 (en) Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization
KR20100087241A (ko) 아데포비어 디피복실 오로트산 염 및 이의 제조방법
JP2012530113A (ja) より良好な生物学的利用能を示すホスホネート誘導体の合成のためのホスホネートシントン
CN108129514A (zh) 磷酸/膦酸衍生物的单一异构体及其医药用途
JP3148139B2 (ja) ホスホナートヌクレオチド化合物
JPH08119981A (ja) イミドビスリン酸、その製造方法およびその使用
JPWO2001064693A1 (ja) ホスホナートヌクレオチド化合物
JPWO1998006726A1 (ja) ホスホナートヌクレオチド化合物
CZ20011145A3 (cs) Antivirové purinové deriváty a jejich použití

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application